These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 15001245

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 01; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 5. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    W V Med J; 2005 Jan 01; 101(4):168-71. PubMed ID: 16296198
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):664-73. PubMed ID: 11849788
    [Abstract] [Full Text] [Related]

  • 8. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1367-82. PubMed ID: 15275722
    [Abstract] [Full Text] [Related]

  • 9. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M, Wallner K, True L, Cash J, Sorace R.
    Urology; 2007 Feb 01; 69(2):334-7. PubMed ID: 17320673
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.
    Urology; 2005 Nov 01; 66(5):1048-53. PubMed ID: 16286122
    [Abstract] [Full Text] [Related]

  • 11. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S.
    Cancer J Sci Am; 1999 Nov 01; 5(5):301-6. PubMed ID: 10526671
    [Abstract] [Full Text] [Related]

  • 12. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 13. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
    Seung SK, Kroll S, Wilder RB, Posner MD, Roach M.
    Cancer J Sci Am; 1998 Sep 01; 4(3):168-74. PubMed ID: 9612598
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Feb 01; 73(2):341-6. PubMed ID: 18597953
    [Abstract] [Full Text] [Related]

  • 16. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2006 Jul 01; 65(3):669-77. PubMed ID: 16682149
    [Abstract] [Full Text] [Related]

  • 17. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Lief JH, Hinerman-Mulroy A, Galbreath RW.
    Brachytherapy; 2003 Jul 01; 2(3):181-8. PubMed ID: 15062141
    [Abstract] [Full Text] [Related]

  • 18. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 19. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L, Huang D, Fearn P, Kattan MW.
    Brachytherapy; 2003 Nov 01; 2(1):26-31. PubMed ID: 15062160
    [Abstract] [Full Text] [Related]

  • 20. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Adamovich E.
    Urology; 2005 Dec 01; 66(6):1150-4. PubMed ID: 16360430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.